What Is the Tariff on Pharmaceuticals From China in 2026?

As of 2026-04-22, pharmaceuticals imported from China face a stacked-duty structure rather than a single headline rate. The new 100% reciprocal pharmaceutical tariff is scheduled to take effect on 2026-07-31 for the first-wave scope, and it sits on top of any base HTS duty plus applicable Section 301 duties. In practice, many Chinese-origin branded pharmaceutical imports move from "high tariff" to "commercially punishing" once the reciprocal layer begins.

TL;DR

• The 2026 China pharmaceutical tariff is a stack: base HTS duty plus Section 301 plus the new 100% reciprocal pharmaceutical layer where applicable.
• The headline number importers talk about is the new 100% reciprocal tariff, but that is not the full landed-cost answer.
• The earliest key date for first-wave pharmaceutical exposure is 2026-07-31.
• The product-level question is not only "is it a drug?" but also origin, HTS line, compound class, and whether the item is exempt.
• If you need a shipment-specific estimate, use the TariffCheck calculator for landed-cost math and the drug tariff lookup for compound-level status.

What is the current tariff on pharmaceuticals from China?

The current tariff on pharmaceuticals from China in 2026 is best understood as three layers:

1. the base Most-Favored-Nation duty tied to the HTS classification
2. the Section 301 duty tied to Chinese origin and the applicable tariff list
3. the new 100% reciprocal pharmaceutical tariff that begins on 2026-07-31 for the first-wave scope

That means the answer is not simply "100%." For some products, the total effective rate is base duty plus 25% Section 301 plus 100% reciprocal pharmaceutical duty. For other products, the base rate may differ, the Section 301 line may be lower or excluded, or the product may be exempt from the reciprocal layer entirely.

The planning mistake importers make is pricing only the reciprocal tariff and forgetting the older duty stack underneath it. TariffCheck treats the China pharmaceutical question the same way it treats any other landed-cost problem: calculate the full stack, then calculate freight, MPF, HMF, broker cost, and last-mile cost on top.

Which 51 drugs are on the list?

The most commercially useful answer is not memorizing every line item by hand. It is knowing whether your specific branded compound falls into the named first-wave list and whether the imported product is Chinese-origin for customs purposes.

Across the current pharmaceutical-tariff discussion, the names importers and patients most often ask about include:

• Ozempic
• Wegovy
• Keytruda
• Xarelto
• Eliquis
• Jardiance
• Farxiga
• Stelara
• Opdivo
• Entresto

Those names matter because they are widely prescribed and price-sensitive. But the importer question is broader: which compounds are inside the first-wave reciprocal scope, and which products remain exempt because they are generic, biosimilar, orphan-only, plasma-derived, fertility-related, or US-manufactured.

That is why the fastest next step is not to guess from brand names alone. Use the drug tariff lookup hub, then cross-check the broader context in related guides such as /blog/drugs-exempt-from-pharmaceutical-tariff-2026 and /blog/trump-100-percent-pharmaceutical-tariff-drugs-affected.

Tariff rate comparison by compound class

Compound class	Base rate	Section 301	New 100% reciprocal	Total effective rate
GLP-1 branded injections	0% to 6.5%	Often 25% when Chinese-origin scope applies	100%	Roughly 125% to 131.5%
Oncology biologics	0% to 6.5%	25% in typical China-origin scenarios	100%	Roughly 125% to 131.5%
Anticoagulants	0% to 6.5%	25% in common branded-import scenarios	100%	Roughly 125% to 131.5%
Small-molecule branded lines	2.5% to 6.5%	7.5% to 25% depending on list treatment	100%	Roughly 110% to 131.5%
Biosimilars	Varies	May face China duties in some contexts	Usually exempt from the reciprocal pharmaceutical layer	Product-specific
All-purpose generics	Varies	China-origin duties may still matter	Usually exempt from the reciprocal pharmaceutical layer	Product-specific

The takeaway is straightforward: the 100% layer is the attention-grabber, but the import-cost problem is still a classification problem. Two products with the same wholesale value can land at very different duty totals depending on HTS line, list treatment, and exemption status.

That is especially true for mixed portfolios. A diabetes injectable, an oncology biologic, and a low-cost generic tablet can all move under different duty logic even if they arrive in the same quarter from the same country.

Procurement teams should therefore stop asking only for the headline tariff rate. The better question is: what is the all-in duty stack on this exact SKU, this exact HTS code, and this exact country-of-origin declaration?

That extra discipline matters most on high-value branded lines, where even a small classification or timing mistake can swing the total duty bill dramatically.

When does the 100% tariff take effect?

The key enforcement date for the first wave is 2026-07-31. That is the deadline most importers, brokers, distributors, and pharmaceutical procurement teams are budgeting around.

There are two reasons this date matters:

• inventory loaded before the effective date may clear under the old stack if entry timing is managed correctly
• inventory loaded after the effective date can experience an immediate and dramatic landed-cost reset

This is why the final week of July 2026 matters much more than broad policy commentary. If a shipment misses the timing window by days, the duty outcome can change by six figures on a commercial lot.

Importers should also remember that exemption status matters just as much as timing. If a product falls into an exempt bucket, the effective date is less important. If it is in the first-wave reciprocal scope, the effective date becomes the budgeting line.

How to estimate your landed cost before July 31

If you need the practical answer instead of the policy answer, use this four-step workflow:

1. Classify the product by HTS code and confirm the exact line item, not just the marketing description.
2. Confirm country of origin under customs rules. Shipping through a third country does not remove Chinese origin if substantial transformation did not occur.
3. Apply the stack: base duty, Section 301, and the reciprocal pharmaceutical layer if the product is in scope.
4. Run the full landed-cost model in the TariffCheck calculator so freight, MPF, HMF, broker cost, and other fees are included.

This is the same reason many importers use TariffCheck before issuing a purchase order. The tariff headline tells you policy risk. The calculator tells you whether the deal still works financially.

Frequently Asked Questions

Is the 100% pharmaceutical tariff already in effect?

Not for the first-wave reciprocal pharmaceutical scope. The key date importers are planning around is 2026-07-31. Before that date, Chinese-origin pharmaceutical imports may still face the older duty stack without the new reciprocal layer.

Which drugs are exempt from the 100% tariff?

The major exempt categories include generics, biosimilars, orphan-only products, plasma-derived therapies, fertility drugs, cell and gene therapies, some veterinary products, and US-manufactured drugs. The fastest way to check a specific product is the drug tariff lookup.

Do Indian-manufactured generics face the same tariff?

No. Section 301 is China-specific, and the reciprocal pharmaceutical layer discussed on this page is tied to Chinese-origin pharmaceutical imports in scope. Indian-manufactured generics may still face normal customs treatment, but not the same China stack.

What is the HTS code for pharmaceutical imports from China?

There is no single HTS code for pharmaceuticals. Drug products span multiple headings and subheadings across HTS chapters 29 and 30, and the exact code depends on the product's chemistry, form, and therapeutic classification.

Can a drug importer avoid the tariff by routing through Mexico?

No. Customs duty liability follows country of origin, not the last shipping stop. If the product remains Chinese-origin under substantial-transformation rules, routing through Mexico does not eliminate Section 301 or reciprocal pharmaceutical exposure.

How does the pharmaceutical tariff affect Medicare drug prices?

The effect is indirect and product-specific. Medicare negotiation, formulary design, and insurer pass-through rules can absorb some of the landed-cost shock, but the tariff still changes manufacturer and importer economics upstream.

Sources

Source: USTR — Section 301 investigations and tariff actions, accessed 2026-04-22 Source: Federal Register — Harmonized Tariff Schedule notices, accessed 2026-04-22 Source: USITC — HTS search and tariff database, accessed 2026-04-22 Source: FDA — Drugs database and labeling resources, accessed 2026-04-22 Source: CBP — Trade and tariffs guidance, accessed 2026-04-22